Drug Trial Radar · NCT05154604
A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Dec 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
156
Planned (sponsor's estimate)
Start
Dec 31, 2021
Primary completion
Aug 31, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921
Conditions
- Advanced Solid Tumours
Interventions
SHR-A1921Drug
Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limited Toxicity (DLT)Time frame: 21 Days (first cycle)
- Maximum Tolerable Dose (MTD)Time frame: 21 Days (first cycle)
- Recommended phase II dose (RP2D)Time frame: Screening up to dose escalation and expansion study completion, appropriately to 1 year
- Adverse EventsTime frame: Screening up to study completion, an average of 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.